NEXTHINK
28.10.2015 08:31:45 CET | Business Wire | Press release
Nexthink®, a pioneer and leader in end-user centric IT Operations Analytics (ITOA), today announced a partnership with Ymor , a leading APM service provider in the Netherlands. Under the agreement, Ymor will be able to provide consulting services, support and implement Nexthink’s IT analytics solutions for its customers.
Ymor unburdens customers through its Ketenbewaking™ service portfolio that protects and optimizes the IT environment by focusing on end-users. By integrating Nexthink’s technology into its offering, Ymor is able to expand and enhance its existing services. In addition to technical, configuration, end-to-end and component monitoring, Ymor can now offer its customers workspace monitoring. Nexthink’s visibility and IT analytics allow Ymor to provide control over the workspace that can lead to fast ROI and financial savings.
"As we strive for ‘end-user happiness,’ workplace monitoring is more important than ever before,” said Martin van den Berge, Director Ymor . “Throughout the workday, most end-users spend at least 5 hours using various applications. Performance issues cause frustration and lead to decreased efficiency for both end-users and the business. Working with Nexthink provides us with an opportunity to measure the end-user experience, to obtain a ‘helicopter view’ of the IT infrastructure, to quickly and easily find the root cause of issues and to achieve the goal of happy end-users.”
Ymor and Nexthink have implemented workplace monitoring with the city of The Hague. Gerard van Lieshout, Sr. Corporate IT Advisor of The Hague : “We use Nexthink to monitor all enterprise desktops, some 7,000 workspaces. By measuring delays, crashes and bottlenecks directly on the desktops, it gives us a better understanding on how our employees use the desktops. This not only allows us to respond better to reported incidents, but also to adjust configurations of the desktops before problems occur.”
“We are excited about the partnership with Ymor and extending our reach in Northern Europe,” said Nathan Wyld, Europe Channel Director at Nexthink . “As a result of this partnership, organisations in the Netherlands can benefit from Nexthink’s IT analytics and Ymor’s outstanding services and support for implementation and optimal use of IT analytics in their environments.”
###
About Ymor:
Ymor is a fast growing and innovative service provider based in Utrecht, which assists the Dutch Top 500 companies in improving the performance of complex IT environments with the goal of unburdening end-users. An organisation may be experiencing problems with performance or availability. It may be building a new application or wish to bring it online. Or there may simply be a need for the complex IT chain to be closely monitored. In all such cases the Ymor ‘Ketenbewaking’ service monitors and optimises the IT environment. Our slogan says it all: “Ymor creates user happiness!”
View source version on businesswire.com: http://www.businesswire.com/news/home/20151028005061/en/
./ContentItem/FormatNexthink and Ymor partnership to meet demand for IT Analytics solutions in the Netherlands and significant customer win: city of The Hague
Contact:
Media contacts:
Nexthink
Victoria Calmon, +33 6
34 77 15 97
victoria.calmon@nexthink.com
www.nexthink.com
or
Ymor
Inge
Vollebregt, +31 610762591
ivollebregt@ymor.nl
www.ymor.nl
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
